Home / About / Governance / Finance & Audit Committee

Finance, Audit & Risk Committee

The Finance & Audit Committee oversees budget, spending, and funding decisions and checks integrity of financial statements, legal compliances, and use of generally accepted accounting principles.

Members of the Committee

Christine is an accomplished, results oriented life science executive with over 25 years of investment, advisory, business development and marketing experience. She is an expert in translating scientific data into market potential and concrete company strategy. Most recently Managing Partner and Founder of Scientia Advisors and Investments where she advised and facilitated fundraising for emerging life sciences companies, Christine has extensive experience in capital markets, strategic planning and analysis.

Christopher’s practice focuses on mergers and acquisitions and finance transactions, as well as advising on governance and general corporate and securities law matters. His clients include private equity and venture capital funds and companies ranging from publicly traded multinationals to early-stage ventures manufacturing.

Warren is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.

Louise St-Onge is the Head of Pricing, Market Access & Government Affairs at Mitsubishi Tanabe Pharma Canada.  She is an accomplished Pharma Leader with >25 years executive experience and track record of achievements in Complex Specialty Pharma.  Recognized as a change agent, she brings unique perspectives gained from her broad commercial & patient access experience, including in setting up Canadian Operations.

Dr. Acker is the Associate Vice-President (Research Integrity Support) where he has leadership responsibilities for building, implementing and managing a framework that supports programs and services encompassing all research integrity areas, including compliance, ethics certification, clinical trials monitoring, human and animal ethics, safeguarding research, and legal requirements related to research at the University of Alberta.

Dr. Jolie is a highly accomplished veterinarian with a diverse academic and professional background. She obtained her Doctor of Veterinary Medicine degree from the University of Ghent, Belgium, and pursued further studies, including internships and research assistantships. Dr. Jolie’s extensive academic journey includes a residency in Swine Medicine and a PhD focusing on airborne contaminants’ impact on swine respiratory health. Over the past 12+ years, she has held significant roles at Pfizer Animal Health and Merck Animal Health, showcasing her expertise in the field and culminating in the completion of an Executive MBA. At Merck Animal Health, she has led pivotal roles, including heading the Global Swine division, shaping strategic direction and ensuring product alignment to meet global market needs.

Observer

Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.

Terms of Reference

View Terms of Reference (PDF)

Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147

Subscribe to GlycoNet’s Newsletter

© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.

en_USEnglish
Scroll to Top